Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

被引：52

作者：

Alffenaar, J. W. C. ^{[1
]}

van der Laan, T. ^{[2
]}

Simons, S. ^{[3
]}

van der Werf, T. S. ^{[4
,5
]}

van de Kasteele, P. J. ^{[6
]}

de Neeling, H. ^{[2
]}

van Soolingen, D. ^{[2
,3
]}

机构：

[1] Univ Groningen, Dept Hosp & Clin Pharm, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[2] Natl Inst Publ Hlth & Environm, Natl Mycobacteria Reference Lab, NL-3720 BA Bilthoven, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dekkerswald, Netherlands

[4] Univ Groningen, Dept Internal Med, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[5] Univ Groningen, Dept Pulm Dis & TB, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[6] Natl Inst Publ Hlth & Environm, Expertise Ctr Methodol & Informat Serv, NL-3720 BA Bilthoven, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2011年 / 55卷 / 03期

关键词：

INTRACTABLE MULTIDRUG-RESISTANT; PHARMACOKINETICS; OXAZOLIDINONES; TOLERABILITY; INHIBITION; EFFICACY;

D O I：

10.1128/AAC.01297-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).

引用

页码：1287 / 1289

页数：3

共 27 条

[1] In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs [J].

Alcalá, L ;

Ruiz-Serrano, MJ ;

Turégano, CPF ;

Garcia de Viedma, D ;

Díaz-Infantes, M ;

Marín-Arriaza, M ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :416-417

[2] Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients [J].

Alffenaar, Jan-Willem C. ;

van Altena, Richard ;

Harmelink, Ilse M. ;

Filguera, Patricia ;

Molenaar, Esther ;

Wessels, A. Mireille A. ;

van Soolingen, Dick ;

Kosterink, Jos G. W. ;

Uges, Donald R. A. ;

van der Werf, Tjip S. .

CLINICAL PHARMACOKINETICS, 2010, 49 (08) :559-565

[3]

Borrell S, 2009, INT J TUBERC LUNG D, V13, P1456

[4] Peripheral neuropathy associated with prolonged use of linezolid [J].

Bressler, AM ;

Zimmer, SM ;

Gilmore, JL ;

Somani, J .

LANCET INFECTIOUS DISEASES, 2004, 4 (08) :528-531

[5] Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections [J].

Brickner, SJ ;

Hutchinson, DK ;

Barbachyn, MR ;

Manninen, PR ;

Ulanowicz, DA ;

Garmon, SA ;

Grega, KC ;

Hendges, SK ;

Toops, DS ;

Ford, CW ;

Zurenko, GE .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :673-679

[6] TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS [J].

COHN, DL .

JOURNAL OF HOSPITAL INFECTION, 1995, 30 :322-328

[7] Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model [J].

Cynamon, MH ;

Klemens, SP ;

Sharpe, CA ;

Chase, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1189-1191

[8]

Dave S, 2009, INDIAN J MED RES, V130, P58

[9] Linezolid for the treatment of multidrug-resistant tuberculosis [J].

Fortún, J ;

Martín-Dávila, P ;

Navas, E ;

Pérez-Elías, MJ ;

Cobo, J ;

Tato, M ;

De la Pedrosa, EGG ;

Gómez-Mampaso, E ;

Moreno, S .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :180-185

[10]

Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758

← 1 2 3 →